PBYI Long Call Strategy

PBYI (Puma Biotechnology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI (Puma Biotechnology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $364.9M, a trailing P/E of 14.95, a beta of 1.23 versus the broader market, a 52-week range of 2.85-7.9, average daily share volume of 358K, a public-listing history dating back to 2012, approximately 172 full-time employees. These structural characteristics shape how PBYI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.23 places PBYI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on PBYI?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current PBYI snapshot

As of May 15, 2026, spot at $6.93, ATM IV 98.90%, IV rank 19.16%, expected move 28.35%. The long call on PBYI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on PBYI specifically: PBYI IV at 98.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a PBYI long call, with a market-implied 1-standard-deviation move of approximately 28.35% (roughly $1.96 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PBYI expiries trade a higher absolute premium for lower per-day decay. Position sizing on PBYI should anchor to the underlying notional of $6.93 per share and to the trader's directional view on PBYI stock.

PBYI long call setup

The PBYI long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PBYI near $6.93, the first option leg uses a $6.93 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PBYI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PBYI shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$6.93N/A

PBYI long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

PBYI long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on PBYI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on PBYI

Long calls on PBYI express a bullish thesis with defined risk; traders use them ahead of PBYI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

PBYI thesis for this long call

The market-implied 1-standard-deviation range for PBYI extends from approximately $4.97 on the downside to $8.89 on the upside. A PBYI long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current PBYI IV rank near 19.16% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PBYI at 98.90%. As a Healthcare name, PBYI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PBYI-specific events.

PBYI long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PBYI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PBYI alongside the broader basket even when PBYI-specific fundamentals are unchanged. Long-premium structures like a long call on PBYI are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PBYI chain quotes before placing a trade.

Frequently asked questions

What is a long call on PBYI?
A long call on PBYI is the long call strategy applied to PBYI (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With PBYI stock trading near $6.93, the strikes shown on this page are snapped to the nearest listed PBYI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PBYI long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the PBYI long call priced from the end-of-day chain at a 30-day expiry (ATM IV 98.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PBYI long call?
The breakeven for the PBYI long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PBYI market-implied 1-standard-deviation expected move is approximately 28.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on PBYI?
Long calls on PBYI express a bullish thesis with defined risk; traders use them ahead of PBYI catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current PBYI implied volatility affect this long call?
PBYI ATM IV is at 98.90% with IV rank near 19.16%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related PBYI analysis